Peritoneal Lavage Liquid Biopsy in Patients With Gastric Cancer

  • End date
    May 8, 2025
  • participants needed
  • sponsor
    Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Updated on 4 October 2022
adjuvant therapy


This study investigates the prognostic role of liquid biopsy in patients with locally advanced gastric cancer.

Liquid biopsy for the detection of circulating tumor DNA will be performed:

  • In the peritoneal lavage, during staging laparoscopy (if indicated) and during curative gastrectomy
  • In plasma, before staging laparoscopy (if indicated), before curative gastrectomy, at hospital discharge, three months after surgery/at the end of adjuvant therapy, and in case of disease recurrence.

The aim of this study is to determine the predictive power of liquid biopsy on overall survival and disease free survival.


The purpose of this prospective observational study is to determine the prognostic role of liquid biopsy for the detection of circulating tumor DNA (ctDNA) in patients with locally advanced gastric cancer.

Patients with cT3-4 and or N+ gastric cancer will proceed to either staging laparoscopy, if preoperative chemotherapy is indicated, or upfront radical surgery within 2 weeks from the last imaging assessment.

Liquid biopsy will be performed with peritoneal lavage and blood samples. Peritoneal lavage is performed with 500 ml of saline, starting from the retrogastric space (100 ml) and following clockwise from right upper quadrant to right lower using 100 ml for each quadrant. At the end of peritoneal lavage, 250 ml of saline solution is collected over the liver, after having positioned the patient in Trendelenburg position and on the right side. Of the collected fluid, 50 mL will be sent for cytological examination and 50 mL will be stocked for ctDNA analyses.

In case of upfront radical surgery, liquid biopsy will be performed at the following time

  • Through blood samples performed before skin incision and 7-10 days after radical surgery;
  • Through peritoneal lavage, immediately after laparotomy/laparoscopy.

In case of staging laparoscopy, liquid biopsy will be performed with blood samples, just before skin incision, and with peritoneal lavage. Patients with no evidence of peritoneal dissemination after staging laparoscopy will undergo induction chemotherapy according to the FLOT scheme or per investigators' judgment, and restaged after 4 cycles. Patients still fulfilling the inclusion criteria will undergo radical surgery within 3 weeks from the last chemotherapy cycle. Patients will then undergo liquid biopsy with the same scheme as for upfront radical surgery.

Patients who are clinically fit, and for whom there is clinical indication, will undergo adjuvant chemotherapy. Blood samples for ctDNA will be collected at the end of the last cycle of adjuvant chemotherapy, or at the end of the third postoperative month for those patients not undergoing postoperative chemotherapy. Then, patients will be followed up according to standard protocols by means of CT scan, CEA assessment and clinical visit every six months for the first three years after surgery and then yearly up to five years after local treatments. Blood samples for ctDNA will be collected at detection of cancer recurrence.

Condition gastric cancers, Gastropathy, stomach adenocarcinoma, Gastric Carcinoma, Stomach Cancer, Gastric Cancer, Gastric Adenocarcinoma, Stomach Discomfort
Clinical Study IdentifierNCT04943406
SponsorFondazione IRCCS Istituto Nazionale dei Tumori, Milano
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Histologically proven gastric or gastro-esophageal junction (GEJ -Siewert type II -III) adenocarcinoma
More than cT2 and/or N + (UICC 8th edition)
Written informed consent

Exclusion Criteria

Presence of ascites or distant metastases
Previous chemotherapy for gastric adenocarcinoma
Previous gastric surgery
Absolute contraindications to surgery
Concomitant malignancies or history of other malignancies in the previous 5 years (with exception of in situ cervical carcinoma, basal cell carcinoma, superficial bladder tumors are allowed if curatively treated)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note